Ketamine for Obsessive-Compulsive Disorder
(MKET2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that you must commit to medication study procedures, which might involve changes to your medication routine.
How is ketamine different from other drugs for OCD?
Ketamine is unique for OCD treatment because it acts rapidly by blocking NMDA receptors, which are involved in glutamate neurotransmission, a pathway linked to OCD. Unlike traditional OCD treatments that take longer to show effects, ketamine can provide quick relief, although its long-term effectiveness and safety in OCD are still under investigation.12345
What data supports the effectiveness of ketamine as a drug for treating obsessive-compulsive disorder?
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with Obsessive-Compulsive Disorder (OCD) who haven't improved after trying at least one standard treatment. Participants must agree to fast before sessions, not join other trials during this study, and commit to the medication procedures.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single infusion of 0.5mg/kg of ketamine with either naltrexone or placebo, with fMRI scans before, during, and after infusion
Follow-up
Participants are monitored for changes in OCD symptoms using the YBOCS scale
What Are the Treatments Tested in This Trial?
Interventions
- Ketamine
- Naltrexone Pill
- Placebo pill
Ketamine is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator